ChemMedChem

Cover image for Vol. 11 Issue 8

Editorial Board Chairs: Antonello Mai, Rainer Metternich. Assoc. Editors: David Peralta, Scott Williams (Sr)

Impact Factor: 2.968

ISI Journal Citation Reports © Ranking: 2014: 19/59 (Chemistry Medicinal); 83/255 (Pharmacology & Pharmacy)

Online ISSN: 1860-7187

Associated Title(s): Angewandte Chemie International Edition, Chemistry - A European Journal, Chemistry – An Asian Journal, ChemBioChem, Medicinal Research Reviews, Molecular Informatics

Press Room

RSS

Have a look at our recent Press Releases. Registered Members of the Press may also access the relevant original communication.

Please address any questions to the Editorial Office or directly to the authors, whose addresses are mentioned in the articles. Please let us know your comments on this service.

Archive: 2010

A Better Target for B-Cell Lymphomas - From a Library of MAG Antagonists to Nanomolar CD22 Ligands

Latest News

A Better Target for B-Cell Lymphomas

From a Library of MAG Antagonists to Nanomolar CD22 Ligands.
Patients suffering from B-cell lymphomas can be treated with antibodies directed against the B-lymphocyte antigen CD20. This therapy is not a cure, however, and new treatments that kill B-cells through different mechanisms are required, especially for patients with indolent lymphoid malignancies. An alternative clinical target for B-cell lymphoma is CD22, a B-cell-specific member of the sialic acid binding Ig-like lectin (Siglec) family that recognizes α2,6-linked sialylated glycans as ligands. When it was demonstrated that B-cell activation can be down-regulated with sialosides, an intensive search for low-molecular-weight high-affinity ligands was initiated.

Read more.

No.Press ReleaseOriginal Communication

05/2011

A Better Target for B-Cell Lymphomas
From a Library of MAG Antagonists to Nanomolar CD22 Ligands
(PDF)

From a Library of MAG Antagonists to Nanomolar CD22 Ligands

Beat Ernst, Universität Basel (Switzerland)


04/2011

Blocking the Channel
A Pharmacologically Active Antagonist of the Two-Pore-Domain Potassium Ion Channel K2P9.1 (TASK-3)
(PDF)

Discovery of a Pharmacologically Active Antagonist of the Two-Pore-Domain Potassium Channel K2P9.1 (TASK-3)

Craig A. Coburn, Merck & Co., West Point, PA (USA)


03/2011

Entry Prohibited for AIDS Viruses
Peptide triazole inhibitors disrupt cell-free HIV-1
(PDF)

Cell-Free HIV-1 Virucidal Action by Modified Peptide Triazole Inhibitors of Env gp120

Irwin Chaiken, Drexel University, Philadelphia (USA)


02/2011

Multitarget Drugs against Prion Diseases
Hybrid lipoic acid derivatives to attack prion disease on multiple fronts
(PDF)

Hybrid Lipoic Acid Derivatives to Attack Prion Disease on Multiple Fronts

Maria Laura Bolognesi, Università di Bologna (Italy)


01/2011

Imaging Against Multiple Sclerosis
An Iodinated Radiotracer Candidate for PET and SPECT Imaging
(PDF)

BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution

Emmanuelle Briard, Novartis Institutes for BioMedical Research, Basel (Switzerland)


SEARCH

SEARCH BY CITATION